The Essential Factors of Establishing Patient-derived Tumor Model

Chen, Chuanzhi; Lin, Wei; Huang, Yingying; Chen, Xiangliu; Wang, Haohao

doi:10.7150/jca.51749

Cited by 34 publications

(41 citation statements)

References 79 publications

(84 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A prolonged implantation time causes tissue metabolism, resulting in a lower engraftment rate [28,29,[34][35][36]50]. The volume of sample should be a certain amount for engraftment [11]. Hoffmann et al reported that no engraftment was detectable when using tumor pieces that were solid 3-to 5-mm cubes [28].…”

Section: Treatment Of Specimensmentioning

confidence: 99%

“…However, the different types of mice described above are used in diverse cancers. This means that use of a suitable type of mouse improves the engraftment rate [11]. For example, nude mice were used for PDX of gastric cancer.…”

Section: Mouse Strainsmentioning

confidence: 99%

“…These characteristics may be associated with the use of nude mice in gastric cancer PDX models [66]. Nude mice are commonly used for PDX of colon [11], renal [67], and pancreatic cancer [21,68]. Transplantation into the subrenal capsule of SCID mice is usually chosen for prostate cancer PDX because a high success rate of 95% has been reported [69].…”

Section: Mouse Strainsmentioning

confidence: 99%

“…PDX models have similar pathological features to the primary tumor and are used as animal experiments for evaluation of drugs, biomarker identification, and precision medicine. The sensitivity of PDX models to drugs is more similar to clinical drug responsiveness because these models have similar genomic features and microenvironment status to the primary tumors [8][9][10][11][12]. The most effective drugs can be identified by screening some anticancer agents in PDX models.…”

Section: Introductionmentioning

confidence: 99%

“…The most effective drugs can be identified by screening some anticancer agents in PDX models. However, this method is not easy to apply because the engrafted tissue does not grow in all cases, and several months may be needed to obtain drug sensitivity data from PDX models [8,[11][12][13]. A PDX cohort with gene information and drug sensitivity data has been suggested.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Patient-Derived Xenograft Models in Cervical Cancer: A Systematic Review

Tanaka

Nishie

Ueda

et al. 2021

IJMS

View full text Add to dashboard Cite

Background: Patient-derived xenograft (PDX) models have been a focus of attention because they closely resemble the tumor features of patients and retain the molecular and histological features of diseases. They are promising tools for translational research. In the current systematic review, we identify publications on PDX models of cervical cancer (CC-PDX) with descriptions of main methodological characteristics and outcomes to identify the most suitable method for CC-PDX. Methods: We searched on PubMed to identify articles reporting CC-PDX. Briefly, the main inclusion criterion for papers was description of PDX created with fragments obtained from human cervical cancer specimens, and the exclusion criterion was the creation of xenograft with established cell lines. Results: After the search process, 10 studies were found and included in the systematic review. Among 98 donor patients, 61 CC-PDX were established, and the overall success rate was 62.2%. The success rate in each article ranged from 0% to 75% and was higher when using severe immunodeficient mice such as severe combined immunodeficient (SCID), nonobese diabetic (NOD) SCID, and NOD SCID gamma (NSG) mice than nude mice. Subrenal capsule implantation led to a higher engraftment rate than orthotopic and subcutaneous implantation. Fragments with a size of 1–3 mm3 were suitable for CC-PDX. No relationship was found between the engraftment rate and characteristics of the tumor and donor patient, including histology, staging, and metastasis. The latency period varied from 10 days to 12 months. Most studies showed a strong similarity in pathological and immunohistochemical features between the original tumor and the PDX model. Conclusion: Severe immunodeficient mice and subrenal capsule implantation led to a higher engraftment rate; however, orthotopic and subcutaneous implantation were alternatives. When using nude mice, subrenal implantation may be better. Fragments with a size of 1–3 mm3 were suitable for CC-PDX. Few reports have been published about CC-PDX; the results were not confirmed because of the small sample size.

show abstract

Section: Treatment Of Specimensmentioning

confidence: 99%

Section: Mouse Strainsmentioning

confidence: 99%

Section: Mouse Strainsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Patient-Derived Xenograft Models in Cervical Cancer: A Systematic Review

Tanaka

Nishie

Ueda

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

Making In Vitro Tumor Models Whole Again

Adine

Mitriashkin

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

As a reductionist approach, patient‐derived in vitro tumor models are inherently still too simplistic for personalized drug testing as they do not capture many characteristics of the tumor microenvironment (TME), such as tumor architecture and stromal heterogeneity. This is especially problematic for assessing stromal‐targeting drugs such as immunotherapies in which the density and distribution of immune and other stromal cells determine drug efficacy. On the other end, in vivo models are typically costly, low‐throughput, and time‐consuming to establish. Ex vivo patient‐derived tumor explant (PDE) cultures involve the culture of resected tumor fragments that potentially retain the intact TME of the original tumor. Although developed decades ago, PDE cultures have not been widely adopted likely because of their low‐throughput and poor long‐term viability. However, with growing recognition of the importance of patient‐specific TME in mediating drug response, especially in the field of immune‐oncology, there is an urgent need to resurrect these holistic cultures. In this Review, the key limitations of patient‐derived tumor explant cultures are outlined and technologies that have been developed or could be employed to address these limitations are discussed. Engineered holistic tumor explant cultures may truly realize the concept of personalized medicine for cancer patients.

show abstract

Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development

Philp

2024

Methods in Molecular Biology

View full text Add to dashboard Cite

The Essential Factors of Establishing Patient-derived Tumor Model

Cited by 34 publications

References 79 publications

Patient-Derived Xenograft Models in Cervical Cancer: A Systematic Review

Patient-Derived Xenograft Models in Cervical Cancer: A Systematic Review

Making In Vitro Tumor Models Whole Again

Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development

Contact Info

Product

Resources

About